Abstract
Background/Purpose
It has been reported that circulating tumor cells (CTCs) can be used to predict survival in metastatic breast cancer. In this preliminary study, we examined the level of CTCs in pancreatic cancer (PC) patients to elucidate whether we could predict survival in PC.
Methods
The eligible subjects, at Tokyo Medical University Hospital, were 26 patients with PC, 11 with chronic pancreatitis, and 10 healthy volunteers. Three PC patients underwent surgery, 18 patients (who were stage IV) were treated with gemcitabine (GEM), and 5 patients received best supportive care (BSC).
Results
The CTC count was 1/7.5 ml blood or higher (defined as positive) in 11 of the 26 patients (42%; mean, 16.9/7.5 ml blood; range, 1-105/7.5 ml blood). Gemcitabine was administered to 6 of the 11 CTC-positive patients (3.8 courses on average). The treatment was continued for more than three courses in 2 patients, in both of whom the CTC count was only 1/7.5 ml blood. Operation was performed in 1 of the 11 CTC-positive patients. The remaining 4 patients of the 11 CTC-positive patients received only BSC. CTC was negative in 15 patients with PC (stage II, 1; stage III, 1; stage IVa, 7; and stage IVb, 6) and in the subjects with benign conditions. The median survival times (MSTs) of the CTC-positive and-negative patients were 110.5 and 375.8 days (P < 0.001). When the analysis was limited to the 14 stage-IVb patients, the MSTs of the CTC-positive and-negative patients were 52.5 and 308.3 days (P < 0.01).
Conclusions
The present study demonstrated that the detection of CTCs in peripheral blood may be useful to predict prognosis in patients with PC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
The Editorial Board of Cancer Statistics in Japan. Cancer statistics in Japan 2005. Tokyo: Foundation for Promotion of Cancer Research; 2005.
Delbeke D, Pinson CW. Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment. J Hepatobiliary Pancreat Surg 2004;11:4–10.
Nagakawa T, Sanada H, Inagaki M, Sugama J, Ueno K, Konishi I. Long-term survivors after resection of carcinoma of the head of the pancreas: significance of histologically curative resection. J Hepatobiliary Pancreat Surg 2004;11:402–408.
Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New Engl J Med 2004;351:781–791.
Cristofanilli M, Hayes DF, Budd T, Ellis MJ, Stopeck A, Reuben JM, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005;23:1420–1430.
Carey RW, Taft PD, Bennett JM, Kaufman S. Carcinocythemia (carcinoma cell leukemia): an acute leukemia-like picture due to metastatic carcinoma cells. Am J Med 1976;60:273–278.
Myerowitz RL, Edwards PA, Sartiano GP. Carcinocythemia (carcinoma cell leukemia) due to metastatic carcinoma of the breast. Cancer 1977;40:3107–3111.
Gallivan MV, Lokich JJ. Carcinocythemia (carcinoma cell leukemia). Report of two cases with English literature review. Cancer 1984;53:1100–1102.
Sile CC, Perry DJ, Nam L. Small cell carcinocythemia. Arch Pathol Lab Med 1999;123:426–428.
Seronie-Vivien S, Mery E, Delord JP, Fillola G, Tkaczuk J, Voigt JJ, et al. Carcinocythemia as the single extension of breast cancer: report of a case and review of the literature. Ann Oncol 2001;12:1019–1022.
Rodriguez-Salas N, Jimenez-Gordo AM, Gonzalez E, Heras B, Zamora P, Espinosa E, et al. Circulating cancer cells in peripheral blood. Arch Cytol 2000;44:237–241.
Kagan M, Howard D, Bendele T, Rao C, Terstappen L. Circulating tumor cells as cancer markers: a sample preparation and analysis system. Tumor markers physiology, pathobiology, technology and applications. Washington D.C.: AACC; 2003, chapter 52, p. 495–498.
Kagan M, Howard D, Bendele T, Mayes J, Silvia J, Repollet M, et al. A sample preparation and analysis system for identification of circulating tumor cells. J Clin Ligand Assay 2002;25:104–110.
Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen L, et al. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci U S A 1998;95:4589–4594.
Gaforio JJ, Serrano MJ, Sanchez-Rovira P, Sirvent A, Delgando-Rodriguez M, Campos M, et al. Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts poor prognosis. Int J Cancer 2003;107:984–990.
Moreno JG, Croce CM, Fischer R, Monne M, Vihko P, Mulholland G, et al. Detection of hematogenous micrometastasis in patient with prostate cancer. Cancer Res 1992;52:6110–6112.
Moreno JG, O’Hara SM, Gross S. Changes in circulating carcinoma cells in metastatic prostate cancer patients correlate with disease status. Urology 2001;58:386–392.
Guller U, Zajac P, Schnider A, Bosch B, Vorburger S, Zuber M, et al. Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg 2002;236:768–776.
Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897–6904.
Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum Ca 19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer 2005;93:195–199.
Author information
Authors and Affiliations
About this article
Cite this article
Kurihara, T., Itoi, T., Sofuni, A. et al. Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result. J Hepatobiliary Pancreat Surg 15, 189–195 (2008). https://doi.org/10.1007/s00534-007-1250-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00534-007-1250-5